Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Orexo Sponsored ADR Representing Ord Shs ORXOY

Healthcare Biotechnology
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The... see more

Current News (OTCQX:ORXOY)

Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis

PR Newswire January 10, 2025

Orexo initiates new study of OX640 in participants with allergic rhinitis

PR Newswire October 25, 2024

Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose

PR Newswire July 16, 2024

Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm

PR Newswire May 10, 2024

Orexo announces that the condition for early redemption of its existing bonds has been fulfilled

PR Newswire April 2, 2024

Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds

PR Newswire March 13, 2024

Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds

PR Newswire March 8, 2024

Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC

PR Newswire February 6, 2024

Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose

PR Newswire November 28, 2023
View More News ››

Opinion & Analysis (OTCQX:ORXOY)

No current opinion is available.
View More Opinion ››

Bullboard Posts (OTCQX:ORXOY)

Be the first to post on this bullboard.

G Mining Ventures Corp.

G Mining Ventures Corp.

G Mining Ventures Corp. is a Canada-based mining company. The Company is engaged in the acquisition, exploration and ...
View More »